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Aims To assess the long-term benefit–risk ratio of drug-eluting (DES) vs. bare-metal stents (BMS) relative to stent size.
Methods
and results
All 826 consecutive BASKET (BAsel Stent Kosten-Effektivita¨ts Trial) patients randomized 2:1 to DES vs. BMS were
followed after 3 years. Data were analysed separately for patients with small stents (,3.0 mm vessel/,4.0 mm
bypass grafts, n ¼ 268) vs. only large stents (3.0 mm native vessels, n ¼ 558). Clinical events were related to
stent thrombosis. Three-year clinical target-vessel revascularization rates remained borderline reduced after DES
[9.9 vs. 13.9% (BMS), P ¼ 0.07], particularly in patients with small stents (10.7 vs. 19.8%, P ¼ 0.03; large stents: 9.5
vs. 11.5%, P ¼ 0.44). Cardiac death/myocardial infarction (MI) rates (12.7 vs. 10.0%, P ¼ 0.30) were similar,
however, death/MI beyond 6 months was higher after DES [9.1 vs. 3.8% (BMS), P ¼ 0.009], mainly due to increased
late death/MI in patients with large stents (9.7 vs. 3.1%, P ¼ 0.006). The results paralleled findings for stent
thrombosis.
Conclusion The clinical benefit of DES was maintained at no overall increased risk of death or death/MI up to 3 years. However,
death/MI rates were increased in DES vs. BMS patients beyond 6 months, particularly in patients with large stents,
paralleling findings for stent thrombosis. Thus, stent size seems to influence the 3-year benefit–risk ratio after
DES implantation.
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Introduction
Late stent thrombosis and its clinical consequences were first
noticed in a systematic and prospective manner in the BAsel Stent
Kosten-Effektivita¨ts LAte Thrombotic Events (BASKET-LATE) trial1
comparing events in an unselected ‘real-world’ patient population
randomized to bare-metal stents (BMS) or drug-eluting stents
(DES). The observed increased rate of late stent thrombosis was
initially surprising and questioned, however, in the meantime con-
firmed by many registry findings and meta-analyses, without affecting
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overall mortality.2–9 Still, conflicting results from registries regarding
longer-term mortality or cardiac death/non-fatal myocardial infarc-
tion (MI) rates were published.2,3,7,8,10,11 A sophisticated analysis of
the BASKET 18-month data defining predictors of outcome and
their interaction with stent type identified a subgroup of patients
with large native vessel stenting as one at particular risk for late clini-
cal problems due to late stent thrombosis, whereas patients with
small vessel or bypass graft stenting seemed to benefit most from
DES implantation.12 Since BASKET-LATE findings were restricted
to an 18-month follow-up, questions arose whether these late
stent thrombosis-related events were a ‘chance finding’ or would
continue to occur virtually exclusively after DES as noted in a large
restistry,13 how this would be after BMS implantation and whether
this was still particularly so in patients with large native vessel stenting
which were actually those enrolled in the pivotal DES trials.3,4
To address these open questions we performed a clinical 3-year
follow-up investigation of all patients included in BASKET.14 Specific
aims were: (i) to assess the 3-year benefit–risk ratio, i.e. the 3-year
rate of clinically indicated target-vessel revascularizations (TVRs) in
relation to 3-year rates of cardiac death/non-fatal MI, (ii) to differ-
entiate early (6 months) from late (.6 months) clinical events,
(iii) to define this benefit–risk ratio in predefined subgroups of
small vs. large stents (cut-off diameter 3.0 mm) and (iv) to relate
these findings to stent thromboses according to the Academic
Research Consortium (ARC) definition.15
Methods
Setting, participants, randomization
and interventions
Patient selection for the BASKET trial has previously been described.14
In short, all 952 consecutive patients treated with angioplasty and
stenting between May 2002 and May 2003 at the University Hospital
of Basel, Switzerland, were evaluated for study inclusion irrespective
of indication for stenting. Only patients with vessels .4 mm in diam-
eter, restenotic lesions, and those without consent were excluded
(n ¼ 126). Thus, the study population consisted of 826 patients,
which was randomized in a 2:1 fashion to receive a DES [Cypherw
Cordis, Johnson&Johnson, Miami Lakes, FL, USA (n ¼ 264);
TAXUSw, Boston Scientific Corporation, Natick, MA, USA (n ¼
281)], and 281 patients to receive a third generation cobalt-chromium
BMS (Visionw, Guidant Corporation, Indianapolis, IN, USA). All
patients gave written informed consent and later on separately for
the extended follow-up. The protocol has been approved by the
Ethics Committee of the University Hospital of Basel, Switzerland.
Patients were subdivided into ‘small-stent’ and ‘large-stent’ patient sub-
groups based on an 18-month analysis, in which all predictors of cardiac
death, non-fatal MI, and non-MI-related TVRwere analysed and multivari-
able predictors tested for their interaction with the stent type
implanted.12 This analysis tested if the effects of DES vs. BMS on
outcome differed significantly relative to clinical and angiographic baseline
characteristics. The use of at least one small stent (,3.0 mm diameter)
or bypass graft intervention showed significant interactions between
stent types and outcome measures in multivariable analyses. Thus,
patients with at least one small stent (,3.0 mm stents) or ‘small’
bypass graft stenting (,4.0 mm) were defined a priori as ‘small-stent’
patients and those with only large (3.0 mm diameter stents) native
vessel stenting as ‘large-stent’ patients for the present study.
Outcomes and follow-up
The primary endpoint of this extended follow-up investigation was the
rate of cardiac death/non-fatal MI after 3 years in DES vs. BMS-treated
patients. Secondary endpoints were non-MI-related TVR (and any
TVR) and major cardiac events (MACE) defined as cardiac death, non-
fatal MI, and non-MI-related TVR including stent thrombosis-related
events as previously defined.1,12,14 Stent thromboses were categorized
into ‘definite’, ‘probable’, and ‘possible’ according to the ARC defi-
nitions,15 the composite of these being total stent thrombosis.
All events were adjudicated by a Critical Events Committee blinded
to stent types. For this 3-year follow-up, the same definitions were
used as in the 18-month analysis of BASKET,1 including stent thrombo-
sis according to ARC definitions.15
In BASKET, all patients were followed after 6 months in the outpa-
tient clinic for primary endpoint assessment which was cost-
effectiveness.16 All patients were treated with dual antiplatelet
therapy up to that point in time and advised to stop clopidogrel
then. Patients were then contacted again after 18 months in the out-
patient clinic, by structured questionnaire and/or by telephone inter-
view to assess the 18-month outcome reported in BASKET-LATE1
and to determine 18-month cost-effectiveness.14 For the extended
3-year follow-up, the same methods and structured questionnaires
as after 18 months were used, forming the basis of the present
report. No control angiography was allowed except for new relevant
ischaemia-related symptoms. If intercurrent hospitalizations and/or
procedures were reported, detailed hospital charts, private physician
records, and death certificates were analysed. Only three patients
living abroad were lost to follow-up, but 16 others, all known to be
alive, gave no consent to further questioning. Thus, follow-up was
complete at 3 years regarding full data in 807 (97.7%) and regarding
survival in 823 patients (99.6%). For time-dependent analysis, follow-up
was censored at the last contact in the other 19 patients (Figure 1).
Statistical analysis
All analyses were performed with the primary aim to compare patients
with DES and BMS. Since this study was planned as follow-up investi-
gation of BASKET, sample size calculations were done for the original
purpose only.14 Therefore, patients were followed in an ‘observational’
manner. Patients were subdivided into ‘small-stent’ and ‘large-stent’
Figure 1 Patient flow diagram.
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subgroups as defined earlier. Quantitative variables are presented as
mean+ standard deviation. Categorical variables are described by
their distribution. Two-group comparisons were done using Fisher’s
exact test for categorical variables and unpaired t-test or Mann–
Whitney U test for quantitative variables. Cumulative incidence was
used to display the proportion of patients with events over time, con-
sidering non-cardiac death as competing risk.17 Hazards were calculated
to compare DES and BMS using Cox-regression. Multivariable survival
analysis using a Cox-regression model which was corrected for all vari-
ables shown in Table 1 [for analyses in ‘large-stent’ and ‘small-stent’ sub-
groups all variables except bypass PCI (percutaneous coronary
intervention) and use of stents ,3.0 mm] was performed to test inde-
pendence of the results of patient and lesion characteristics. Finally, a
landmark analysis was performed dividing the entire follow-up into
initial 6 months, the primary endpoint period of BASKET, and the fol-
lowing 30 months (months 7–36) period.18 All calculations were per-
formed with the use of a commercially available statistical package
(SPSS 15.0), using a significance level of 0.05 and two-sided tests.
Results
Baseline characteristics of the whole patient population as well as
of the two subgroups are summarized in Table 1. Overall, patients
represent a typical ‘real-world’ population with high rates of acute
coronary syndrome and ‘off-label DES’ use, cardiovascular risk
factors, and multivessel disease with several high risk character-
istics, such as multiple and long-vessel stenting. There were no sig-
nificant differences between patients with DES and BMS at baseline
except for stent length which was somewhat longer in DES
patients. However, baseline characteristics differed significantly
between ‘small-stent’ and ‘large-stent’ patients, as defined for this
study.12 Sixty per cent of patients stopped dual antiplatelet
therapy immediately after 6 months and 83 and 80% were on
monotherapy after 18 and 36 months, respectively, with no differ-
ences between the stent groups and no influence on outcome.
Three-year event rates of drug-eluting
stent vs. bare-metal stent
The benefit of DES in reducing the rate of non-MI-related TVRs for
clinical symptoms persisted up to 3 years (P ¼ 0.07), particularly in
patients with small stents (P ¼ 0.03); however, this benefit was
small and non-significant in patients with large stents (P ¼ 0.44;
Figure 2 and Table 2). This result was achieved without a significant
difference in total or cardiac mortality in the total study population
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics
Overall
(n ¼ 826)
Drug-eluting
stents (n ¼ 545)
Bare-metal
stents (n ¼ 281)
Subgroups
Large stents
(n ¼ 558)
Small stents
(n ¼ 268)
P-value
(subgroups)
Male 650 (79%) 422 (79%) 223 (79%) 435 (78%) 215 (80%) 0.47
Age (years) 64+11 64 (11) 64 (11) 63+11 66+11 ,0.001
Diabetes 154 (19%) 93 (17) 61 (22) 97 (17%) 57 (22%) 0.16
Hypertension 550 (67%) 358 (66%) 192 (68%) 354 (63%) 196 (73%) 0.008
Hypercholesterol 628 (76%) 414 (76%) 214 (76%) 420 (75%) 206 (77%) 0.54
Current smoking 238 (29%) 151 (28%) 87 (31%) 184 (33%) 54 (20%) ,0.001
Previous MI 226 (27%) 151 (28%) 75 (27%) 126 (23%) 100 (37%) ,0.001
Previous PCI 133 (16%) 91 (17%) 42 (15%) 78 (14%) 55 (21%) 0.02
Previous CABG 105 (13%) 70 (13%) 35 (12%) 33 (6%) 72 (27%) ,0.001
Presentation
STEMI 176 (21%) 115 (21%) 61 (22%) 142 (25%) 34 (13%) ,0.001
Unstable 301 (36%) 200 (37%) 101 (36%) 201 (36%) 100 (37%)
Stable 349 (42%) 230 (42%) 119 (42%) 215 (39%) 134 (50%)
GPIIb/IIIa blockers 212 (26%) 141 (26%) 71 (25%) 156 (28%) 56 (21%) 0.03
Multivessel disease 566 (69%) 371 (68%) 195 (69%) 347 (62%) 219 (82%) ,0.001
Bypass graft PCI 47 (6%) 34 (6%) 13 (5%) 0 (0%) 47 (18%) ,0.001
CTO 28 (3%) 14 (3%) 14 (5%) 11 (2%) 17 (6%) 0.002
Bifurcations 44 (5%) 27 (5%) 17 (6%) 20 (4%) 24 (9%) 0.002
Stented segments 1.5+0.7 1–6 (0–7) 1–5 (0–7) 1.3+0.6 1.8+0.8 ,0.001
Stents/patient 1.9+1.1 1–9 (1–1) 1–9 (1–0) 1.3+0.9 2.3+1.1 ,0.001
Total stent length (mm) 34+20 34 (20) 32 (20) 30+17 42+24 ,0.001
Stent length/lesion (mm) 28+15 28 (15) 27 (16) 26+14 31+17 ,0.001
1 stent(s) ,3.0 mm 229 (28%) 160 (29%) 69 (25%) 0 (0%) 229 (85%) ,0.001
Off-label usea 548 (66%) 376 (69%) 172 (61%) 327 (59%) 221 (82%) ,0.001
Abbreviations: CABG, coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation MI; GP, glycoprotein.
aOff-label use defined according to recent FDA guidelines.
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Figure 2 Cumulative incidence of events in the total study population (left) as well as in subgroups with small and large stents, respectively. Cardiac death (A), cardiac death/MI (myocardial
infarction) (B), non-MI-related TVR (target-vessel revascularization) (C) and MACE (major cardiac events) (D), comparing patients treated with DES (drug-eluting stent) vs. those treated with BMS
(bare-metal stent). Note that scales of cumulative incidence differ between (A), (B) and (C), and (D).
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as well as in the two subgroups. Overall, also cardiac death/MI, the
primary endpoint of this study, was not different between stent
types (Figure 2). However, the 3-year cardiac death/MI rate was sig-
nificantly higher in patients with large stents treated with DES than
in those treated with BMS. In contrast in patients with small stents,
there was a trend favouring DES over BMS (Table 2, Figure 2). Thus,
the benefit–risk ratio expressed as combination of cardiac death/
MI and TVR, i.e. the 3-year MACE rate, was similar for the two
stent types overall and in ‘large-stent’ patients, but showed a
marked advantage for DES over BMS in ‘small-stent’ patients
(Table 2, Figure 3). Multivariable analysis revealed that the effects
of DES vs. BMS on the primary endpoint overall, and in the two
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Table 2 Outcome events after 3 years
Overall Large stents Small stents
DES (n ¼ 545) BMS (n ¼ 281) P-value DES (n ¼ 358) BMS (n ¼ 200) P-value DES (n ¼ 187) BMS (n ¼ 81) P-value
Total death 8.3% 6.8% 0.49 7.3% 5.5% 0.49 10.2% 9.9% 1.0
Cardiac death 4.8% 3.2% 0.36 4.2% 2.0% 0.23 5.9% 6.2% 1.0
Cardiac death/MI 12.7% 10.0% 0.31 13.4% 6.5% 0.02 11.2% 18.5% 0.12
Non-MI TVR 9.9% 13.9% 0.10 9.5% 11.5% 0.47 10.7% 19.8% 0.05
Any TVR 14.7% 17.5% 0.29 14.0% 14.1% 0.98 16.0% 25.9% 0.06
MACE 21.1% 22.8% 0.59 20.9% 17.0% 0.27 21.4% 37.0% 0.01
Figure 3 Three-year cumulative incidence of cardiac death/non-fatal MI (myocardial infarction) subdivided into early and late events. Cardiac
death/MI over 3 years (left) and subdivided into the first 6 months and thereafter (right) for all patients (top), patients with small stents (middle)
and patients with large stents (bottom).
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subgroups did not differ if other patient or lesion-specific charac-
teristics were considered. Thus, after correction for baseline
characteristics, no significant effects of DES use on cardiac death/
MI was found overall (HR ¼ 1.24, 95% CI 0.79–1.943, P ¼ 0.35)
nor in patients with small stents (HR ¼ 0.69, 95% CI 0.33–1.46,
P ¼ 0.33). In contrast, DES use was an important risk factor for
cardiac death/MI in ‘large-stent’ patients (HR ¼ 2.08, 95% CI
1.11–3.89).
Difference between early and late events
The landmark analysis separating early from late clinical events is
shown in Figure 3 for cardiac death/MI. Overall, there was an
early non-significant benefit of DES, which contrasted to a signifi-
cantly higher rate of cardiac death/MI beyond 6 months (DES 9.1%,
BMS 3.8%, P ¼ 0.009). This was mainly due to an increased rate of
such late events in patients with large stents (9.7 vs. 3.1%, P ¼
0.006), whereas this difference was smaller and not significant in
patients with small stents (7.9 vs. 5.8%, P ¼ 0.57). This resulted
in overall yearly cardiac death/MI rates after 6 months at 3.6%
per year in DES (95% CI 2.6–4.6%) and 1.5% per year (95% CI
0.6–2.5%) in BMS-treated patients. These yearly event rates after
6 months were 3.9% (95% CI 2.6–5.2%) vs. 1.3% (95% CI 0.3–
2.3%) for ‘large-stent’ and 3.1% (95% CI 1.5–4.7%) vs. 2.3%
(95% CI 0.1–4.6%) for ‘small-stent’ patients, respectively.
Stent thrombosis-related clinical events
Overall, stent thrombosis-related clinical events were noted in
9.0% of DES and 7.5% of BMS-treated patients (P ¼ 0.51)
without significant differences in any of the ARC stent thrombosis
categories (Figure 4). However, there was a higher rate of total
stent thrombosis-related events in patients with large stents
treated with DES, whereas an opposite trend was seen in
‘small-stent’ patients. The latter trend was related to a higher
rate of target-vessel MIs within the first 6 months in this group
and no relevant difference thereafter. In ‘large-stent’ patients,
however, there was no significant difference in the rate of early
stent thrombosis between stents, but, after 6 months, stent throm-
boses occurred more frequently after DES vs. BMS implantation.
Stent thrombosis-related events were noted more often in both
stent groups after a first follow-up TVR, which was always per-
formed using a DES irrespective of the initial stent. Overall, rates
were 5.2% after a first TVR vs. 2.7% with no previous reinterven-
tion in patients initially treated with DES and 8.8 vs. 2.8% in
patients initially treated with BMS.
Discussion
The present findings of the first 3-year-follow-up study of an unse-
lected patient population randomized to DES or BMS irrespective
of indication for stenting provides new important insights into the
late benefit–risk relation of DES vs. BMS; results confirm that
overall benefits of DES, i.e. the reduced need for repeat revascu-
larization due to restenotic events, are maintained long-term,
and that overall safety, i.e. the rate of cardiac death or non-fatal
MI, is similar to that seen after BMS. New are observations that
the safety problems discussed after first generation DES implan-
tation in fact increase with time and become clinically relevant
late after stenting, particularly in patients treated with large
native vessel stenting. This is markedly different from what was
found after BMS implantation in this randomized study; late throm-
botic events after BMS were a rare event, 2.5 times less frequent
than after DES, and this rate was lower in ‘large-stent’ patients,
adding to the different risk–benefit ratio between small and
large-stent patients. These results were paralleled by findings of
stent thromboses suggesting a clear association between late
stent thrombosis and late clinical events. Thus, hypotheses formu-
lated in an earlier analysis12 are substantiated by hard clinical find-
ings of the present study and call for caution in the unrestricted use
of first generation DES.
In the present clinical study, the reduced need for TVRs due to
new symptoms was numerically smaller compared with previous
observations resulting in a P-value of only 0.07 for the difference.
This may be due to the fact that repeat angiography was only
allowed for clinical symptoms. A scintigraphic substudy of
BASKET19 showed an additional significant reduction in target
vessel ischaemia by DES in absence of relevant symptoms (10.4%
after BMS, 5.4% after DES, P ¼ 0.05). Thus, the present findings
are in agreement with TVR results of previous long-term
studies.5,8,9 Importantly, the benefit of DES in reducing TVR
rates was mainly found in patients with small stents and was very
small in patients with large stents. The notion that the benefit
of DES is larger in small stents has been shown19 and led to
the summary recommendation by the National Institutes of
Clinical Excellence in England to restrict the use of DES to small
stents.
In the present study, there were no overall increased rates of
the safety endpoints, cardiac or total death nor of cardiac death/
MI, in DES compared with BMS-treated patients, although this
study was not powered to prove this definitively. This reassuring
finding was not confirmed, however, in the larger subgroup of
patients with large stents in which cardiac death/MI occurred
more frequently after DES compared with that after BMS implan-
tation. In fact in multivariable analysis, DES use was the most
important risk factor for cardiac death/MI in this subgroup inde-
pendent of all other patient and lesion-related characteristics. In
contrast, there was a trend towards a benefit in this primary end-
point in patients with small stents after 3 years similar to earlier
randomized observations with small DES within the initial year of
stenting.20 In the benefit–risk balance expressed as MACE, this
resulted in no significant difference in DES vs. BMS-treated patients
overall, nor in ‘large-stent’ patients, but a persistent and marked
advantage of DES in ‘small-stent’ patients.
The present analysis supports the notion of a different benefit–
risk relation early and late after DES implantation.1,6 Whereas early
thrombotic events seem to be influenced strongly by procedural
factors21 and are heavily dependent on the continuation of dual
antiplatelet therapy,22,23 late events are mainly related to incom-
plete or inhomogeneous healing24 and may occur despite contin-
ued dual antiplatelet therapy.1,13,22 It has been noted that the
rate of ‘definite’ late stent thrombosis increases  0.6% per
year13 and that this figure increases up to 2.2%25 or 2.75% per
year26 for definite, possible and probable stent thrombosis
events according to the ARC definition, not much different from
the present ‘real-world’ findings. In addition, the present study
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shows that late stent thrombosis-related clinical events occur also
after BMS implantation, but 2.5 less frequently than that after
DES use. The fact that late clinical events paralleled findings of
stent thrombosis suggests a distinct relation between them.
However, the occurrence of stent thrombosis shows a different
pattern after BMS implantation; it is a rare event if large stents
are used, but not if small stents are used. Thus, in patients with
small stents the difference in stent thrombosis rates after DES
vs. BMS implantation is so low relative to the large benefit of
DES that the overall clinical outcome up to 3 years favours DES
use in these patients. In contrast, this balance is much worse for
patients with large stents mainly due to the small clinical TVR
benefit noted previously,27 arguing against a general DES use in
these patients. The increased rate of late stent thrombosis in
large DES may be explained by the complexity of patients and
lesions treated (mainly more acute coronary syndromes/acute
MIs) compared with earlier studies, the higher chance of a clinically
apparent event if a large vs. a small vessel is occluded and is in
agreement with recent autopsy findings where stent thrombosis
was found in 44% of stents 3.5 mm vs. 9% of stents 2.5 mm
(P, 0.01; R. Virmani, personal communication, Local Drug Deli-
very Meeting, Geneva, January 2007).
The present study is limited by the fact that BASKET was not
initially planned to detect late clinical events related to late stent
Figure 4 Three-year stent thrombosis rates subdivided into early and late events. Stent thrombosis rates for all patients (top), subgroups with
small stents (middle) and large stents (bottom) for the entire 3-year observation period (left panels), the initial 6 months (middle panels) and
months 7–36 (right panels). ARC (Academic Research Consortium) ‘definite’ thromboses in green, ‘probable’ orange and ‘possible’ in blue:
P-values for total stent thrombosis.
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thrombosis. This is particularly true for the subgroup comparison
relating to stent size which would need a much larger sample size
for definite answers. However, the present data are supported by
the fact that the findings up to 18 months are enhanced in the
present 3-year-follow-up study with cardiac death/MI curves separ-
ating significantly up to 3 years (Figure 3 top, bottom). If 18-month
results would have been a chance finding, the opposite would be
anticipated. In addition, the study was not powered to assess the
magnitude of late stent thromboses definitively, however, it is
the first randomized investigation presenting detailed data col-
lected prospectively. Finally, since all findings relating to subgroup
analyses (i.e. stent size) are only hypothesis generating, they may
not be interpreted as stipulating that DES should not be used in
‘label’ indications, particularly since stent size and ‘on-’ vs. ‘off-label’
indications are not at all congruent.
Conclusions
Taken together, the findings of this long-term study suggest, based
on randomized data, that baseline stent size seems to determine
the long-term benefit–risk balance in a relevant way: patients
with at least one small stent have a large benefit of DES in all clini-
cal endpoints, which is not significantly reduced by late stent
thrombosis-related events up to 3 years. In contrast, patients
with large stents have a small clinical benefit on restenosis-related
events only and, therefore, late stent thrombosis-related problems
become relevant after 3 years. It remains uncertain how this will
translate into an even longer-term outcome balance which,
however, will also be affected by the natural progression of under-
lying coronary disease. This uncertainty and the possible impact of
newer DES on this benefit–risk balance, particularly regarding the
large group of patients in need of large stents in daily practice, is
addressed prospectively in the ongoing European multicentre
BASKET-PROVE (BASKET-PROspective Validation Examination),
in which 2323 consecutive patients with large vessel stenting
were randomized to a first vs. a second generation DES vs. a
BMS28 (results expected in 2010).
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A thrombus stuck in the ostium of the coronary artery
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A 55-year-old male ex-smoker was admitted
to our hospital with a 2-h history of anterior
chest and back pain. His vital signs and serum
biomarkers including troponin I were
normal. An electrocardiogram showed
atrial fibrillation without an ST-elevation.
Plain computed tomography (CT) imaging
revealed the high density in the proximal
segment of the right coronary artery
(RCA), which suggests a thrombus in this
vessel (Panel A), and axial view and curved
planar reconstruction (CPR) in
contrast-enhanced CT visualized a large
thrombus of 20  12 mm stuck at the
orifice of RCA (Panels B and C). Thus,
acute coronary syndrome caused by emboli
was most likely diagnosis. Thrombolysis
was chosen instead of percutaneous coron-
ary intervention to avoid systemic emboliza-
tion. We used pamiteplase, a recombinant
tissue plasminogen activator, as fibrinoytic
agent for intravenous therapy and warfarin
as anticoagulant. The magnitude of
ST-elevation was gradually increased. Atrial
fibrillation was converted to normal sinus
rhythm but an ST-segment remained elev-
ated in II, III, and aVF for 18 h after thrombo-
lysis therapy. The serum creatine phosphokinase was increased, and reached a peak of 2119 IU/L at 27 h after the onset. On the 15th day,
the CPR image showed disappearance of the thrombus at the orifice, and there was no evidence of atherosclerotic plaques in the entire
RCA (Panel D). These findings allowed us to diagnose that ACS was caused by a thrombus stuck in the ostium of RCA. Cardiac CT may
have advantages to detect coronary thrombo-embolism in the patients with atrial fibrillation.
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